News of Note—AstraZeneca’s FluMist, Dynavax’s Heplisav-B head to ACIP, and more

In this week's news of note, AstraZeneca's FluMist and Dynavax's Heplisav-B present in front of a CDC panel. (Pixabay)

Here is some other vaccine news of note for the week.

> AstraZeneca’s FluMist, hoping to make a comeback after being struck down for two flu seasons, and Dynavax’s Heplisav-B, aiming to challenge GlaxoSmithKline’s Engerix-B, are both under consideration at a CDC panel today. Meeting schedule

> A new bill proposed by Sen. Richard Blumenthal, D-Conn., Ed Markey, D-Mass., and several other fellow senators calls for $1 billion over the next five years for development of a universal flu vaccine. Associated Press story

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Preclinical data published in the journal Vaccine showed Moderna’s mRNA vaccine platform might work to develop vaccines to prevent human cytomegalovirus. Release

> The Khushi Baby system, which includes a necklace with a computer chip that stores up to two years of vaccination records for young children, won the grand prize from Johnson & Johnson’s GenH Challenge for Maternal and Child Health. Release